BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson disease among LRRK2 mutation carriers: A metabolomic study. Neurology 2020;95:e3428-37. [PMID: 32999056 DOI: 10.1212/WNL.0000000000010863] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Maloney MT, Wang X, Ghosh R, Andrews SV, Maciuca R, Masoud ST, Caprioli RM, Chen J, Chiu C, Davis SS, Ho AC, Nguyen HN, Propson NE, Reyzer ML, Davis OB, Deen MC, Zhu S, Di Paolo G, Vocadlo DJ, Estrada AA, de Vicente J, Lewcock JW, Arguello A, Suh JH, Huntwork-rodriguez S, Henry AG. LRRK2 Kinase Activity Regulates Parkinson’s Disease-Relevant Lipids at the Lysosome.. [DOI: 10.1101/2022.12.19.521070] [Reference Citation Analysis]
2 Lin H, Cheng M, Lo C, Lin G, Liu F. Metabolomic Signature of Diabetic Kidney Disease in Cerebrospinal Fluid and Plasma of Patients with Type 2 Diabetes Using Liquid Chromatography-Mass Spectrometry. Diagnostics 2022;12:2626. [DOI: 10.3390/diagnostics12112626] [Reference Citation Analysis]
3 Crotty GF, Keavney JL, Alcalay RN, Marek K, Marshall GA, Rosas HD, Schwarzschild MA. Planning for Prevention of Parkinson Disease: Now Is the Time. Neurology 2022;99:1-9. [DOI: 10.1212/wnl.0000000000200789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Crotty GF, Schwarzschild MA. What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology 2022;99:34-41. [PMID: 35970592 DOI: 10.1212/WNL.0000000000200238] [Reference Citation Analysis]
5 Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C. Path to Parkinson Disease Prevention: Conclusion and Outlook. Neurology 2022;99:76-83. [PMID: 35970586 DOI: 10.1212/WNL.0000000000200793] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Niotis K, West AB, Saunders-Pullman R. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Genetically At-Risk Cohorts. Neurology 2022;99:10-8. [PMID: 35970585 DOI: 10.1212/WNL.0000000000200812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Fu X, Li H, Chen X, Cai J, Yao T, Song L, Cen M, Wu J. Associations between urinary caffeine and caffeine metabolites and cognitive function in older adults. Nutr Neurosci 2022;:1-11. [PMID: 35715983 DOI: 10.1080/1028415X.2022.2071809] [Reference Citation Analysis]
8 Reichmann H. [Caffeine, Chocolate and Adenosine A2A Receptor Antagonists in the Treatment of Parkinson's Disease]. Fortschr Neurol Psychiatr 2022. [PMID: 35584767 DOI: 10.1055/a-1785-3632] [Reference Citation Analysis]
9 Mori A, Chen JF, Uchida S, Durlach C, King SM, Jenner P. The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease. Molecules 2022;27:2366. [PMID: 35408767 DOI: 10.3390/molecules27072366] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Jost WH, Tönges L. [Adenosine A2A Receptor Antagonists as a Treatment Option for Parkinson's Disease?]. Fortschr Neurol Psychiatr 2022. [PMID: 35226930 DOI: 10.1055/a-1771-6225] [Reference Citation Analysis]
11 Schumacher-schuh A, Bieger A, Borelli WV, Portley MK, Awad PS, Bandres-ciga S. Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases. Front Neurol 2022;12:792227. [DOI: 10.3389/fneur.2021.792227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Cuzzolaro M, Melchionda N. Parkinson’s Disease and Eating and Weight Disorders. Hidden and Lesser-known Disordered Eating Behaviors in Medical and Psychiatric Conditions 2022. [DOI: 10.1007/978-3-030-81174-7_31] [Reference Citation Analysis]
13 Kovacs G, Reimer L, Jensen PH. Endoplasmic Reticulum-Based Calcium Dysfunctions in Synucleinopathies. Front Neurol 2021;12:742625. [PMID: 34744980 DOI: 10.3389/fneur.2021.742625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fong RY, Kuhnle GGC, Crozier A, Schroeter H, Ottaviani JI. Validation of a high-throughput method for the quantification of flavanol and procyanidin biomarkers and methylxanthines in plasma by UPLC-MS. Food Funct 2021;12:7762-72. [PMID: 34231610 DOI: 10.1039/d1fo01228b] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Mori A, Cross B, Uchida S, Kerrick Walker J, Ristuccia R. How Are Adenosine and Adenosine A2A Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis? Biomedicines 2021;9:1027. [PMID: 34440231 DOI: 10.3390/biomedicines9081027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hu Y, Wang Z, Liu L, Zhu J, Zhang D, Xu M, Zhang Y, Xu F, Chen Y. Mass spectrometry-based chemical mapping and profiling toward molecular understanding of diseases in precision medicine. Chem Sci 2021;12:7993-8009. [PMID: 34257858 DOI: 10.1039/d1sc00271f] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
17 Leclerc M, Dudonné S, Calon F. Can Natural Products Exert Neuroprotection without Crossing the Blood-Brain Barrier? Int J Mol Sci 2021;22:3356. [PMID: 33805947 DOI: 10.3390/ijms22073356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
18 . Selected Literature Watch. Journal of Caffeine and Adenosine Research 2021;11:23-4. [DOI: 10.1089/caff.2021.29019.slw] [Reference Citation Analysis]
19 Janitschke D, Lauer AA, Bachmann CM, Grimm HS, Hartmann T, Grimm MOW. Methylxanthines and Neurodegenerative Diseases: An Update. Nutrients 2021;13:803. [PMID: 33671099 DOI: 10.3390/nu13030803] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
20 Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism Relat Disord 2020;80 Suppl 1:S45-53. [PMID: 33349580 DOI: 10.1016/j.parkreldis.2020.10.024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
21 Ren X, Chen JF. Caffeine and Parkinson's Disease: Multiple Benefits and Emerging Mechanisms. Front Neurosci 2020;14:602697. [PMID: 33390888 DOI: 10.3389/fnins.2020.602697] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
22 Crotty GF, Lo RY, Schwarzschild MA. If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames? Mov Disord 2020;35:1727-30. [PMID: 33068466 DOI: 10.1002/mds.28240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]